Association between predictors of interest and time to VTE in all 3 cohorts combined of newly diagnosed adult-type diffuse glioma cases
| Predictors . | Univariable . | Multivariable . | ||
|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Age (in years) | 1.04 (1.03-1.06) | 1.02E-06 | 1.02 (1-1.05) | .08 |
| Sex (female vs male) | 0.91 (0.56-1.49) | .708 | — | — |
| Ethnicity (non-Hispanic vs Hispanic) | 0.94 (0.23-3.84) | .926 | — | — |
| WHO grade | — | — | ||
| 3 vs 2 | 1.65 (0.3-8.99) | .565 | 1.35 (0.24-7.74) | .734 |
| 4 vs 2 | 8.06 (1.96-33.11) | .004 | 1.63 (0.26-10.08) | .6 |
| Histology (oligo vs astro) | 0.11 (0.01-0.77) | .027 | — | — |
| Smoker (current vs never or former) | 1.12 (0.51-2.46) | .779 | — | — |
| Length of hospital stay (in days) | 1.06 (1.01-1.11) | .03 | — | — |
| BMI | 1.07 (1.02-1.11) | .003 | 1.09 (1.04-1.15) | 2.024E-4 |
| History of VTE | 10.88 (6.27-18.86) | <2e-16 | 12.28 (6.27-24.06) | 2.74E-13 |
| Radiotherapy | 2.16 (0.87-5.4) | .098 | — | — |
| Temozolomide | 1.48 (0.64-3.44) | .361 | — | — |
| Bevacizumab | 1.39 (0.72-2.67) | .326 | — | — |
| Hemoglobin | 1 (0.88-1.13) | .972 | — | — |
| Platelet count | 0.97 (0.93-1.01) | .161 | — | — |
| WBC count | 1.2 (0.8-1.79) | .374 | 0.95 (0.57-1.59) | .855 |
| Hypertension | 2.27 (1.39-3.72) | .001 | 0.84 (0.43-1.66) | .617 |
| Hyperlipidemia | 1.67 (0.99-2.8) | .054 | — | — |
| Asthma | 1.86 (0.74-4.63) | .185 | 2.01 (0.75-5.36) | .162 |
| Hypothyroidism | 1.35 (0.64-2.83) | .429 | 0.48 (0.2-1.13) | .093 |
| Blood coagulation disorder(s) | 1.27 (0.31-5.18) | .742 | — | — |
| IDHmut vs IDHwt | 0.14 (0.05-0.39) | 1.54E-4 | 0.4 (0.09-1.86) | .243 |
| 1p/19q Codeletion | 0.09 (0.01-0.63) | .016 | — | — |
| MGMT promoter methylated | 0.71 (0.42-1.19) | .19 | 0.77 (0.42-1.4) | .391 |
| EGFR amplificated/mutated | 1.99 (1.14-3.48) | .015 | — | — |
| Predictors . | Univariable . | Multivariable . | ||
|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Age (in years) | 1.04 (1.03-1.06) | 1.02E-06 | 1.02 (1-1.05) | .08 |
| Sex (female vs male) | 0.91 (0.56-1.49) | .708 | — | — |
| Ethnicity (non-Hispanic vs Hispanic) | 0.94 (0.23-3.84) | .926 | — | — |
| WHO grade | — | — | ||
| 3 vs 2 | 1.65 (0.3-8.99) | .565 | 1.35 (0.24-7.74) | .734 |
| 4 vs 2 | 8.06 (1.96-33.11) | .004 | 1.63 (0.26-10.08) | .6 |
| Histology (oligo vs astro) | 0.11 (0.01-0.77) | .027 | — | — |
| Smoker (current vs never or former) | 1.12 (0.51-2.46) | .779 | — | — |
| Length of hospital stay (in days) | 1.06 (1.01-1.11) | .03 | — | — |
| BMI | 1.07 (1.02-1.11) | .003 | 1.09 (1.04-1.15) | 2.024E-4 |
| History of VTE | 10.88 (6.27-18.86) | <2e-16 | 12.28 (6.27-24.06) | 2.74E-13 |
| Radiotherapy | 2.16 (0.87-5.4) | .098 | — | — |
| Temozolomide | 1.48 (0.64-3.44) | .361 | — | — |
| Bevacizumab | 1.39 (0.72-2.67) | .326 | — | — |
| Hemoglobin | 1 (0.88-1.13) | .972 | — | — |
| Platelet count | 0.97 (0.93-1.01) | .161 | — | — |
| WBC count | 1.2 (0.8-1.79) | .374 | 0.95 (0.57-1.59) | .855 |
| Hypertension | 2.27 (1.39-3.72) | .001 | 0.84 (0.43-1.66) | .617 |
| Hyperlipidemia | 1.67 (0.99-2.8) | .054 | — | — |
| Asthma | 1.86 (0.74-4.63) | .185 | 2.01 (0.75-5.36) | .162 |
| Hypothyroidism | 1.35 (0.64-2.83) | .429 | 0.48 (0.2-1.13) | .093 |
| Blood coagulation disorder(s) | 1.27 (0.31-5.18) | .742 | — | — |
| IDHmut vs IDHwt | 0.14 (0.05-0.39) | 1.54E-4 | 0.4 (0.09-1.86) | .243 |
| 1p/19q Codeletion | 0.09 (0.01-0.63) | .016 | — | — |
| MGMT promoter methylated | 0.71 (0.42-1.19) | .19 | 0.77 (0.42-1.4) | .391 |
| EGFR amplificated/mutated | 1.99 (1.14-3.48) | .015 | — | — |
Astro, IDHmut grade 2 to 4 astrocytoma; EGFR, epidermal growth factor receptor; MGMT, O-6-methylguanine–DNA methyltransferase; oligo, IDHmut, 1p/19q-codeleted WHO grade 2 to 3 oligodendroglioma, --, not included because was not significant on univariable anlaysis.